BioXmark®
Soft tissue tumor marking for high-precision radiation therapy (e.g., prostate, lung, rectal cancer)
ApprovedActive
Key Facts
Indication
Soft tissue tumor marking for high-precision radiation therapy (e.g., prostate, lung, rectal cancer)
Phase
Approved
Status
Active
Company
About Nanovi
Nanovi is a Copenhagen-based medical device company focused on precision oncology through its proprietary liquid fiducial markers. Its lead product, BioXmark®, is a CE-marked liquid marker designed to enhance target visibility for high-precision radiation therapy in humans, while PetXmark™ serves the veterinary oncology market. The company was acquired by CQ Medical in October 2023, signaling a successful exit and integration into a larger commercial entity. Nanovi's technology platform, developed in collaboration with DTU, addresses a critical need for flexible and accurate soft tissue marking across cancer types.
View full company profile